• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	Apimeds Pharmaceuticals US, Inc. (APUS)
	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014
Balance Sheet Date		2026-Mar-31	2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31
Fiscal Period		Q1-FY2026	Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024
Total Assets		141,219,157$	164,183,736$	9,250,036$	10,546,681$	259,904$	13,057$				422,076$
Total Current Assets		13,153,203$	13,983,859$	9,086,108$	10,349,549$	259,904$	13,057$				422,076$
Cash and Cash Equivalents		979,534$	1,636,655$	6,986,617$	8,735,323$	250,432$	3,455$				410,481$
Receivables
Other Current Assets		48,500$	48,500$
Assets Held for Sale in Short Term
Total Noncurrent Assets		128,065,954$	150,199,877$	163,928$	197,132$	0$	0$				0$
Goodwill
Other Intangible Assets
Physical Assets		56,592$	51,626$	34,188$	13,137$
Other Noncurrent Assets
Assets Held for Sale in Long Term
Total Liabilities		14,703,698$	10,835,909$	1,089,384$	809,002$	2,020,422$	1,371,178$				390,207$
Total Current Liabilities		14,584,883$	10,706,455$	1,089,384$	809,002$	1,770,422$	1,024,334$				123,316$
Accounts Payable
Short Term Debt
Short Term Capital Lease Obligations		52,339$	39,578$
Other Current Liabilities				3,657$	9,906$
Total Noncurrent Liabilities		118,815$	129,454$	0$	0$	250,000$	346,844$				266,891$
Long Term Debt
Long Term Capital Lease Obligations		118,815$	129,454$
Other Noncurrent Liabilities
Total Equity		126,515,459$	153,347,827$	8,160,652$	9,737,679$	(1,760,518$)	(1,358,121$)	(1,046,488$)	(713,967$)	(264,604$)	31,869$
Equity to Minority
Equity to Common Shareholders		126,515,459$	153,347,827$	8,160,652$	9,737,679$	(1,760,518$)	(1,358,121$)	(1,046,488$)	(713,967$)	(264,604$)	31,869$
Additional Paid-In Capital		163,654,524$	163,540,358$	17,272,661$	17,068,433$	2,954,764$	2,954,764$				2,954,764$
Retained Earnings		(45,452,913$)	(10,393,061$)	(9,237,769$)	(7,456,514$)	(4,794,321$)	(4,391,924$)				(3,001,934$)
Treasury Stock
Capital Lease Obligations			169,032$

Copy Table ✓